HLS Therapeutics Inc.
HLTRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | -0.27 | -0.13 | 1.94 |
| FCF Yield | 9.33% | 12.59% | 2.89% | 3.21% |
| EV / EBITDA | 7.82 | 14.71 | 18.04 | 17.78 |
| Quality | ||||
| ROIC | -6.80% | -5.46% | -5.97% | -2.68% |
| Gross Margin | 84.11% | 87.91% | 91.90% | 93.38% |
| Cash Conversion Ratio | -0.41 | -0.57 | -0.72 | -1.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.70% | 1.67% | 3.09% | 3.48% |
| Free Cash Flow Growth | -48.79% | 129.61% | -43.00% | 133.73% |
| Safety | ||||
| Net Debt / EBITDA | 2.85 | 5.10 | 4.43 | 3.03 |
| Interest Coverage | -0.76 | -1.18 | -1.84 | -0.90 |
| Efficiency | ||||
| Inventory Turnover | 0.99 | 0.80 | 0.56 | 0.45 |
| Cash Conversion Cycle | 62.67 | -157.05 | -130.57 | 34.08 |